 Amber Berning
Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma, Mucinous | 2 | 2022 | 76 | 0.820 |
Why?
| | Ovarian Neoplasms | 4 | 2023 | 595 | 0.800 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.750 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 10 | 0.750 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 76 | 0.680 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 49 | 0.320 |
Why?
| | Endometrial Neoplasms | 2 | 2023 | 205 | 0.290 |
Why?
| | Heart Injuries | 1 | 2023 | 42 | 0.190 |
Why?
| | Mouth Neoplasms | 1 | 2023 | 90 | 0.190 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 278 | 0.190 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 76 | 0.180 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 195 | 0.180 |
Why?
| | Myocarditis | 1 | 2023 | 102 | 0.180 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2025 | 356 | 0.170 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 542 | 0.170 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2022 | 89 | 0.170 |
Why?
| | beta Catenin | 2 | 2023 | 254 | 0.170 |
Why?
| | Heart Rate | 1 | 2025 | 855 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 530 | 0.160 |
Why?
| | Immunohistochemistry | 1 | 2023 | 1716 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2023 | 641 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2023 | 561 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1149 | 0.120 |
Why?
| | Retinopathy of Prematurity | 1 | 2018 | 181 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2018 | 503 | 0.110 |
Why?
| | Mutation | 2 | 2023 | 4075 | 0.110 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 33 | 0.090 |
Why?
| | DNA Polymerase II | 2 | 2023 | 35 | 0.090 |
Why?
| | Placenta | 1 | 2018 | 786 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2023 | 2214 | 0.080 |
Why?
| | Middle Aged | 5 | 2025 | 36215 | 0.080 |
Why?
| | Female | 8 | 2025 | 78845 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 534 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2878 | 0.060 |
Why?
| | Humans | 10 | 2025 | 145475 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 38 | 0.050 |
Why?
| | Adult | 3 | 2023 | 40777 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2023 | 1321 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 147 | 0.050 |
Why?
| | Prognosis | 2 | 2023 | 4316 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2023 | 25 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2025 | 252 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 53 | 0.050 |
Why?
| | Phosphatidylinositols | 1 | 2023 | 57 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 166 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2025 | 242 | 0.050 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 19 | 0.050 |
Why?
| | Carcinogens | 1 | 2023 | 123 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 79 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 654 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2023 | 228 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 133 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2062 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 55 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.030 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.030 |
Why?
| | Aged | 3 | 2025 | 26153 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2019 | 310 | 0.030 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 165 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 881 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2018 | 173 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3155 | 0.030 |
Why?
| | Risk | 1 | 2018 | 919 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1471 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 3542 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 987 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1426 | 0.030 |
Why?
| | Fetus | 1 | 2018 | 804 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 765 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3623 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 8057 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2023 | 8333 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11772 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2018 | 17291 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 6013 | 0.020 |
Why?
| | Young Adult | 1 | 2023 | 14219 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5905 | 0.010 |
Why?
| | Mice | 1 | 2023 | 18329 | 0.010 |
Why?
| | Pregnancy | 1 | 2018 | 7202 | 0.010 |
Why?
| | Infant | 1 | 2018 | 10077 | 0.010 |
Why?
| | Adolescent | 1 | 2023 | 22530 | 0.010 |
Why?
| | Animals | 1 | 2023 | 38030 | 0.010 |
Why?
| | United States | 1 | 2018 | 16098 | 0.010 |
Why?
| | Male | 1 | 2025 | 72843 | 0.010 |
Why?
|
|
Berning's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|